How to Obtain a Drug Manufacturing License in China: 2026 Guide

A comprehensive guide for foreign pharmaceutical companies navigating China’s drug manufacturing licensing regime under the NMPA’s 2026 regulatory framework.

Introduction

China’s pharmaceutical market is the second-largest in the world, valued at over USD 200 billion, and continues to grow at a compound annual growth rate of approximately 6-8%. For foreign pharmaceutical companies seeking to manufacture drugs within China — whether for the domestic market or for export — obtaining a Drug Manufacturing License (药品生产许可证, yàopǐn shēngchǎn xǔkězhèng) is the foundational regulatory requirement. This license, administered by the National Medical Products Administration (NMPA, formerly CFDA), is mandatory for any entity that produces pharmaceutical products within Chinese territory.

The regulatory landscape has undergone significant transformation in recent years. The 2019 Drug Administration Law (revised), the 2020 Good Manufacturing Practice (GMP) certification reforms, and the 2025-2026 NMPA streamlining initiatives have collectively reshaped the licensing process. This guide provides foreign pharmaceutical companies with a practical, step-by-step roadmap to obtaining a Drug Manufacturing License in China under the current 2026 regulatory framework.

It is important to note that China distinguishes between several categories of manufacturing licenses. A standard Drug Manufacturing License covers the production of finished pharmaceutical products. Separate or supplementary licenses are required for traditional Chinese medicine (TCM) preparations, active pharmaceutical ingredients (APIs), excipients, and packaging materials. This guide focuses primarily on the standard Drug Manufacturing License for Western pharmaceutical products, though many principles apply across categories.

Regulatory Framework and Governing Authorities

The National Medical Products Administration (NMPA)

The NMPA is the primary national regulatory authority responsible for drug regulation in China, including manufacturing licensing. Under the NMPA’s 2026 organizational structure, the Center for Drug Evaluation (CDE) handles drug registration and clinical trial approvals, while the Center for Food and Drug Inspection (CFDI) conducts on-site GMP inspections. Provincial-level Medical Products Administrations (MPAs) play a significant role in manufacturing license issuance and routine supervision.

Key Legislation and Regulations

The following legislative instruments form the legal foundation for drug manufacturing licensing in China:

• Drug Administration Law of the People’s Republic of China (2019 Revision) — the primary statute governing all drug-related activities, including manufacturing
• Administrative Regulations on Drug Manufacturing Licenses (NMPA Order No. 47, 2020) — the specific implementing rules for license applications, renewals, and management
• Good Manufacturing Practice for Pharmaceutical Products (2020 Revised Edition, aligned with PIC/S standards) — the quality standard that all licensed manufacturers must meet
• Drug Registration Regulation (NMPA Order No. 27, 2020) — governs the relationship between manufacturing licenses and drug product registration
• Measures for the Supervision and Administration of Drug Manufacturing (2021) — ongoing compliance requirements for licensed manufacturers
• NMPA Guidelines on Cross-Provincial Drug Manufacturing Licensing (2024) — clarifies jurisdictional issues for multi-site operations
• NMPA 2025-2026 Administrative Simplification Directives — reduced documentation requirements and accelerated processing timelines

International Harmonization

China’s pharmaceutical regulatory framework has progressively aligned with international standards. In 2024, the NMPA formally acceded to the Pharmaceutical Inspection Co-operation Scheme (PIC/S), committing China’s GMP standards to full alignment with international norms. China’s ICH membership (since 2017) has further harmonized drug registration and quality requirements with those of the United States, European Union, and Japan. These developments have simplified the path for foreign pharmaceutical companies whose manufacturing facilities already comply with US FDA or EU EMA GMP standards, as the NMPA now accepts certain foreign GMP inspection reports under mutual recognition arrangements.

Eligibility Requirements for Foreign Applicants

Foreign pharmaceutical companies may apply for a Chinese Drug Manufacturing License through a Wholly Foreign-Owned Enterprise (WFOE) or a Sino-foreign joint venture. Since the 2022 relaxation of foreign investment restrictions in the pharmaceutical sector under the Special Administrative Measures (Negative List), foreign investors may hold majority or full ownership of drug manufacturing enterprises in most categories, with certain restrictions remaining on vaccines and blood products for national security reasons.

Basic Qualification Criteria

The NMPA evaluates applicants against the following criteria:

1. Legal Entity: The applicant must be a legally registered enterprise in China, with a business scope that explicitly includes drug manufacturing
2. Qualified Personnel: The enterprise must employ personnel with appropriate professional qualifications, including a legally designated “Person in Charge” (企业负责人) and a “Quality Person in Charge” (质量负责人) who meet the educational and experience requirements specified in GMP regulations
3. Premises and Facilities: Manufacturing premises must meet GMP requirements for cleanliness, environmental control, and facility design appropriate to the dosage forms to be manufactured
4. Equipment and Instruments: Production and testing equipment must be appropriately qualified, calibrated, and maintained
5. Quality Management System: A comprehensive quality management system covering all aspects of manufacturing, testing, storage, and distribution must be in place
6. Product Registration: For most drug products, a valid Drug Registration Certificate (药品注册证书) or Marketing Authorization must be held or applied for in conjunction with the manufacturing license

The Application Process: Step by Step

Step 1: Pre-Application Preparation (3-6 Months)

The pre-application phase is the most critical and time-intensive stage. Foreign companies should begin by engaging a qualified Chinese regulatory affairs consultant or law firm with specific expertise in NMPA manufacturing licensing. Key preparatory activities include:

• Feasibility Assessment: Determine which drug categories and dosage forms will be manufactured, as this determines facility design, equipment requirements, and GMP classification
• Site Selection: Evaluate provincial-level MPA jurisdictions, as processing times and local requirements may vary. Key pharmaceutical manufacturing hubs include Jiangsu (Taizhou, Suzhou), Zhejiang (Hangzhou, Shaoxing), Shandong (Jinan, Weifang), and Guangdong (Guangzhou, Shenzhen). Many provincial governments offer incentives for pharmaceutical manufacturing investment, including tax holidays, subsidized land, and expedited permitting
• Facility Design: Engage an engineering firm with pharmaceutical GMP design experience to plan the facility. The design must comply with China’s GMP requirements, which are detailed in the 2020 GMP and its annexes for specific dosage forms
• Personnel Recruitment: Identify and recruit key personnel, particularly the Quality Person in Charge, who must hold a pharmacist qualification recognized in China and have at least five years of experience in pharmaceutical quality management
• Environmental Impact Assessment: Submit an Environmental Impact Assessment (EIA) to the local Bureau of Ecology and Environment, as drug manufacturing facilities are subject to environmental permitting requirements

Step 2: Facility Construction and Qualification (6-12 Months)

This phase involves the physical construction or renovation of the manufacturing facility, followed by comprehensive qualification activities. The timeline varies significantly depending on the complexity of the facility and the dosage forms involved.

Key activities include:

• Construction and Installation: Build or renovate the facility according to the approved design, including cleanrooms classified according to GMP requirements (Grade A, B, C, or D environments depending on the manufacturing process)
• Equipment Qualification: Perform Design Qualification (DQ), Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) for all critical manufacturing and testing equipment
• Utility Qualification: Qualify HVAC systems, purified water systems, compressed air systems, and other utilities that directly impact product quality
• Process Validation: Develop and execute process validation protocols for the manufacturing processes to be licensed
• Analytical Method Validation: Validate analytical methods for quality control testing according to Chinese Pharmacopoeia (ChP) standards
• Cleaning Validation: Develop and execute cleaning validation protocols to prevent cross-contamination between products

Step 3: GMP Self-Assessment and Documentation (2-3 Months)

Before submitting the license application, the enterprise must complete a comprehensive GMP self-assessment and prepare the required documentation package. The documentation requirements include:

• Site Master File: A detailed description of the manufacturing site, facilities, equipment, and quality management system (aligned with the PIC/S Site Master File format)
• Quality Management System Documentation: Quality manual, standard operating procedures (SOPs), specifications, and records covering all GMP-relevant activities
• Personnel Qualification Files: Curriculum vitae, professional qualifications, and training records for key personnel
• Facility Layout Drawings: Detailed floor plans showing cleanroom classifications, material flows, personnel flows, and waste handling
• Equipment List and Qualification Reports: Comprehensive listing of all manufacturing and testing equipment with corresponding qualification documentation
• Product Quality Review: For existing products, a Product Quality Review (PQR) covering manufacturing history and quality trends
• Stability Data: For products to be manufactured, accelerated and long-term stability data as required by the product registration

Step 4: Submission of the License Application (1-2 Months for Review)

The Drug Manufacturing License application is submitted to the provincial-level MPA in the jurisdiction where the manufacturing facility is located. Since the 2025 administrative simplification reforms, the application may be submitted through the NMPA’s online portal (https://zwfw.nmpa.gov.cn).

The required application documents include:

1. Drug Manufacturing License Application Form (药品生产许可证申请表) — the standard form prescribed by the NMPA
2. Business License of the enterprise
3. Site Master File
4. Facility layout drawings and floor plans
5. List of key manufacturing and testing equipment
6. Curriculum vitae and qualification certificates of the Person in Charge and Quality Person in Charge
7. GMP self-assessment report
8. Product listing and corresponding Drug Registration Certificates (if applicable)
9. Environmental protection approval documents
10. Fire safety inspection certificate
11. Other documents as required by the provincial MPA

The provincial MPA reviews the application within 30 working days (reduced from 45 working days under the 2025 reforms). If the application is complete and meets the formal requirements, the MPA will schedule a GMP on-site inspection.

Step 5: GMP On-Site Inspection (2-4 Weeks Preparation + 3-5 Days Inspection)

The GMP on-site inspection is conducted by the provincial MPA or, in the case of certain high-risk products or complex facilities, by the CFDI. The inspection follows the NMPA’s GMP Inspection Guidelines, which are aligned with PIC/S inspection standards.

During the inspection, inspectors will evaluate:

• Premises and Facilities: Verification that facilities meet GMP design and operational requirements
• Equipment: Inspection of equipment qualification status, calibration, and maintenance records
• Personnel: Interviews with key personnel to assess GMP knowledge and competence
• Documentation: Review of the quality management system documentation and records
• Production: Observation of manufacturing processes, including aseptic processing techniques where applicable
• Quality Control: Inspection of the quality control laboratory, equipment, and testing capabilities
• Validation Status: Review of process validation, cleaning validation, and analytical method validation reports
• Complaint and Recall Systems: Evaluation of systems for handling product complaints and conducting recalls

Following the inspection, the inspection team issues a written inspection report and a list of any observed deficiencies. The enterprise is typically given a specified period (usually 30-90 days) to address deficiencies, with a follow-up inspection or document review to verify corrective actions.

Foreign companies should note that while the NMPA has made progress toward mutual recognition of foreign GMP inspections, on-site inspections by Chinese authorities are still conducted in most cases for initial license applications. However, companies with a strong track record of compliance with FDA or EMA GMP standards generally find that the inspection process proceeds more smoothly, as the inspectors are familiar with international GMP norms.

Step 6: License Issuance (10-15 Working Days After Inspection Clearance)

Once the GMP inspection is cleared and any deficiencies are resolved, the provincial MPA issues the Drug Manufacturing License. The license includes the following information:

• License number and enterprise name
• Registered address and manufacturing address
• Scope of manufacturing (specific dosage forms and product categories)
• Validity period (typically 5 years)
• Issuing authority and date of issue

The total timeline from the start of pre-application preparation to license issuance is typically 12-24 months for a new greenfield facility, or 8-14 months for an existing facility being adapted for pharmaceutical manufacturing.

Post-License Compliance Obligations

Obtaining the Drug Manufacturing License is not the end of the regulatory journey. Licensed manufacturers are subject to ongoing compliance obligations under Chinese law:

Annual Self-Inspection and Reporting

Licensed manufacturers must conduct annual GMP self-inspections and submit an annual report to the provincial MPA. The annual report covers production volume, quality incidents, regulatory inspections, and any significant changes to the facility, equipment, or quality system.

Change Management

Any significant changes to the manufacturing facility, equipment, production processes, or quality management system must be reported to the provincial MPA. Major changes may require prior approval or a follow-up GMP inspection. Changes are classified into three categories under NMPA regulations:

• Category A (Major Changes): Require prior approval and, in some cases, a new GMP inspection. Examples include adding a new dosage form, relocating the manufacturing site, or changing a critical manufacturing process
• Category B (Moderate Changes): Require notification to the MPA within a specified timeframe (typically 30 days). Examples include adding new manufacturing equipment that does not change the process or facility classification
• Category C (Minor Changes): May be documented internally and reported in the annual self-inspection report. Examples include replacing equipment with an identical model or updating SOPs

GMP Compliance Maintenance

Licensed manufacturers must maintain GMP compliance on an ongoing basis. The provincial MPA conducts routine GMP inspections every 2-3 years and may conduct unannounced “for cause” inspections in response to quality concerns or adverse event reports. As of 2026, the NMPA has increased the frequency of risk-based inspections, focusing on facilities manufacturing high-risk products such as sterile injectables, biologics, and controlled substances.

License Renewal

The Drug Manufacturing License is valid for 5 years. An application for renewal must be submitted to the provincial MPA at least 6 months before the expiration date. The renewal process involves a review of the enterprise’s compliance history, quality performance, and current GMP status. A renewal inspection may be required if significant changes have occurred or if the previous inspection identified serious deficiencies.

Common Challenges and Risk Mitigation Strategies

Regulatory Interpretation Differences

Foreign pharmaceutical companies often encounter differences between Chinese GMP interpretations and those in their home jurisdictions. Engaging a qualified Chinese regulatory consultant early in the process is essential to bridge these interpretation gaps. Companies should also consider conducting a mock GMP inspection with experienced Chinese auditors before the official inspection.

Language and Documentation Barriers

All application documents, SOPs, quality records, and inspection responses must be in Chinese. The translation of technical GMP documentation is a significant undertaking. Companies should invest in professional translation services with pharmaceutical expertise and allow adequate time for document review and approval by Chinese regulatory personnel.

Timeline Management

Foreign companies accustomed to more predictable regulatory timelines in their home markets often underestimate the total time required for Chinese licensing. Building buffer time into project plans — particularly for facility construction, equipment importation, and document preparation — is essential. The 2025-2026 administrative simplification reforms have improved processing times, but unexpected delays can still occur at the provincial MPA level.

Data Exclusivity and Regulatory Data Protection

Since the 2020 amendments to the Drug Administration Law, China has implemented a 6-year data exclusivity period for innovative drugs and a 3-year period for modified new drugs. Foreign companies should ensure that their data protection strategies are aligned with Chinese requirements and that confidential manufacturing information is appropriately protected in regulatory submissions.

Intellectual Property Considerations

The manufacturing license application requires disclosure of manufacturing processes and quality control methods. Foreign companies should consider filing appropriate patent applications in China before disclosing proprietary manufacturing information in license applications. China’s patent law now provides for patent term extension for pharmaceutical patents (up to 5 years) and a patent linkage system that connects drug registration with patent status.

Conclusion

Obtaining a Drug Manufacturing License in China is a complex, multi-stage process that requires careful planning, significant investment, and a thorough understanding of the Chinese regulatory environment. The 2025-2026 reforms have made the process more streamlined and transparent, and China’s alignment with international GMP standards (through PIC/S accession and ICH membership) has created a more familiar regulatory environment for foreign pharmaceutical companies.

Nevertheless, the process remains demanding. A successful outcome depends on early engagement with qualified regulatory advisors, meticulous preparation of facilities and documentation, and a commitment to maintaining GMP compliance throughout the license lifecycle. Foreign companies that invest properly in the licensing process find that China offers a world-class manufacturing environment with access to the world’s second-largest pharmaceutical market.

Disclaimer: This guide provides general information and does not constitute legal advice. Regulatory requirements may vary based on specific circumstances, product categories, and provincial-level implementations. Foreign pharmaceutical companies should engage qualified Chinese legal and regulatory professionals for advice tailored to their specific situation.